Insider Buying Signals Boost Confidence in ENGENE’s Cancer‑Vaccine Stock
Insider buys in ENGENE THERAPEUTICS hint at hidden upside for its cancer‑vaccine pipeline—yet volatility and lack of revenue keep risk high. Explore the bullish signals and cautious outlook.
3 minutes to read